



Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com



Editor Profiles: Guest Editors of the Special Column on Machine Learning in Drug Discovery



Dr. Guobo Li is a Professor at Sichuan University, Chengdu, China. He studied for an undergraduate degree in Pharmaceutical Engineering at Xihua University, Chengdu, China. He moved to Sichuan University for PhD studies with Professor Shengyong Yang in Medicinal Chemistry. He subsequently moved to the University of Oxford for postdoctoral studies in

the research group of Professor Christopher J Schofield, a Fellow of the Royal Society. He became Associate Professor in the West China School of Pharmacy at Sichuan University in 2016, and became Professor of Medicinal Chemistry in 2021. His research interests focus on the development of new computational tools, new data resources and new web servers to assist basic science and drug discovery research, particularly targeting metalloenzymes, and the development of new chemical probes, new hits/leads or drug candidates to exploit metalloenzyme biological/pathological roles and therapeutic potentials. He has published over 60 peer-reviewed articles. He served as editor of the book *Drug Discovery Targeting Metalloenzymes*.



Dr. Changguo Zhan is an Endowed Professor of Pharmaceutical Sciences and Director of the Molecular Modeling and Biopharmaceutical Center at the University of Kentucky, Lexington, KY, USA. He earned a PhD in Molecular Physics from the Institute of Molecular Science in Japan and a PhD in Physical Chemistry from the University of Notre Dame, Notre Dame, IN, USA. He also completed postdoctoral

training at Columbia University, New York, NY, USA. He joined the University of Kentucky College of Pharmacy as an Associate Professor in 2003 and was promoted to Full Professor in 2007. His research focuses on computational drug design, drug discovery, and drug development. Dr. Zhan has authored more than 450 peer-reviewed publications and holds over 50 patents and patent applications. Two of his patented drug candidates have completed Phase II clinical trials, and a third is currently undergoing Investigational New Drug (IND) submission to the U.S. Food and Drug Administration (FDA). His honors include the 2005 American Chemical Society (ACS) Emerging Computational Technology Prize and the 2016 American Association of Pharmaceutical Scientists (AAPS) Research Achievement Award in Drug Discovery and Development Interface. He received the National Institute on Drug Abuse (NIDA) Translational Avant-Garde Award in 2015 and was a co-recipient of the 2014 AAPS Innovation in Biotechnology Award. He was elected a Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 2010 and a Fellow of the National Academy of Inventors (NAI) in 2022.

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apsb.2026.06.019>

2211-3835 © 2026 Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).